We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Umecrine Cognition Raises New Funds to Support Clinical Development

News   Mar 11, 2016

 
Umecrine Cognition Raises New Funds to Support Clinical Development
 
 
 

RELATED ARTICLES

Tucatinib Against Stage IV HER2+ Breast Cancer, Phase III Trial Results Promising

News

Study results show that the combination of the investigational drug tucatinib with standard of care treatment (including the drugs trastuzumab and capecitabine) nearly tripled one-year progression-free survival (33% vs. 12%), and nearly doubled the two-year overall survivor (45% vs. 27%) in women with HER2+ metastatic breast cancer.

READ MORE

Criteria for Cancer Clinical Trials Might Be Too Strict

News

Federal regulations may be keeping lung cancer patients out of clinical trials simply because the patients are on medications that might affect the electrical system of the heart. The regulations may be preventing al proportion of patients from participating in clinical trials.

READ MORE

Trial Suggests Immunotherapy Is Superior to Chemotherapy in Some Children With Relapsed Leukemia

News

New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia (B-ALL) that has relapsed.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE